Trial Profile

Double-Blind, Placebo-Controlled Dose-Finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vidutolimod (Primary)
Indications Allergic rhinoconjunctivitis; Hypersensitivity
Focus Therapeutic Use
Sponsors Cytos Biotechnology

Most Recent Events

31 Jul 2009 Primary endpoint 'Symptom score' (Rhinoconjunctivitis symptom and medication scores) has been met according to a Cytos Biotechnology media release. Secondary endpoints have also been met.
31 Jul 2009 Results will be presented at an upcoming meeting according to a Cytos Biotechnology media release. Results were also reported in the media release.
28 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com